Suchergebnisse - "SARS-CoV-2"

PubPharm (3.230)

1

Immunogenicity and safety of SARS-CoV-2 recombinant protein subunit vaccine (IndoVac) adjuvanted with alum and CpG 1018 in Indonesian adults : A phase 3, randomized, active-controlled, multicenter trial

enthalten in: Vaccine | 2024

von Nurdin, A. | Movieta Nency, Y. | Maddeppungeng, M. | +24

2

Prevalence of neutralizing antibodies against SARS-CoV-2 using a rapid serological test in health workers of a Spanish Department of Health in Alicante (Spain) before the booster dose of the vaccine

enthalten in: Revista clinica espanola | 2024

von Montagud, A. | Llenas-García, J. | Moragues, R. | +7

3

SARS-CoV-2 IgG Levels as Predictors of XBB Variant Neutralization, Israel, 2022- and 2023

enthalten in: Emerging infectious diseases | 2024

von Lustig, Y. | Canetti, M. | Indenbaum, V. | +11

4

Mucosal prime-boost immunization with live murine pneumonia virus-vectored SARS-CoV-2 vaccine is protective in macaques

enthalten in: Nature communications | 2024

von Kaiser, J. | Nelson, C. | Liu, X. | +24

5

SARS-CoV-2 seroprevalence among children in Greece during Omicron variant period

enthalten in: European journal of pediatrics | 2024

von Dimopoulou, D. | Sotiri, D. | Kousi, D. | +26

6

Altered transcriptomic immune responses of maintenance hemodialysis patients to the COVID-19 mRNA vaccine

enthalten in: eLife | 2024

von Chang, Y. | Huang, K. | Lee, J. | +22

7

Comparison of effectiveness and safety of molnupiravir versus sotrovimab for COVID-19 : A systematic review and meta-analysis

enthalten in: Immunity, inflammation and disease | 2024

von Amani, B. | Amani, B.

8

Characterizing Infections in Two Epidemic Waves of SARS-CoV-2 Omicron Variants : A Cohort Study in Guangzhou, China

enthalten in: Viruses | 2024

von Qu, L. | Xie, C. | Qiu, M. | +18

9

pGM-CSF as an adjuvant in DNA vaccination against SARS-CoV-2

enthalten in: International journal of biological macromolecules | 2024

von Liu, C. | Xue, R. | Li, G. | +11

10

Immunogenicity and safety of a recombinant COVID-19 vaccine (ZF2001) as heterologous booster after priming with inactivated vaccine in healthy children and adolescents aged 3-17 years : an open-labeled, single-arm clinical trial

enthalten in: BMC infectious diseases | 2024

von Huang, T. | Hu, Q. | Zhou, X. | +10

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[323]